CDK4/6 inhibitors—such as abemaciclib, palbociclib, and ribociclib—are clinically approved for use in advanced hormone receptor-positive (HR+), HER2-negative breast cancer, where they are often paired with endocrine therapy and have demonstrated marked clinical benefit [36]. This evidence concerns the gene NR4A1 and breast cancer.